|Home | About | Journals | Submit | Contact Us | Français|
Digalloyl-resveratrol (di-GA) is a synthetic compound aimed to combine the biological effects of the plant polyhydroxy phenols gallic acid and resveratrol, which are both radical scavengers and cyclooxygenase inhibitors exhibiting anticancer activity. Their broad spectrum of activities may probably be due to adjacent free hydroxyl groups.
Protein activation and expression were analysed by western blotting, deoxyribonucleoside triphosphate levels by HPLC, ribonucleotide reductase activity by 14C-cytidine incorporation into nascent DNA and cell-cycle distribution by FACS. Apoptosis was measured by Hoechst 33258/propidium iodide double staining of nuclear chromatin and the formation of gaps into the lymphendothelial barrier in a three-dimensional co-culture model consisting of MCF-7 tumour cell spheroids and human lymphendothelial monolayers.
In HL-60 leukaemia cells, di-GA activated caspase 3 and dose-dependently induced apoptosis. It further inhibited cell-cycle progression in the G1 phase by four different mechanisms: rapid downregulation of cyclin D1, induction of Chk2 with simultaneous downregulation of Cdc25A, induction of the Cdk-inhibitor p21Cip/Waf and inhibition of ribonucleotide reductase activity resulting in reduced dCTP and dTTP levels. Furthermore, di-GA inhibited the generation of lymphendothelial gaps by cancer cell spheroid-secreted lipoxygenase metabolites. Lymphendothelial gaps, adjacent to tumour bulks, can be considered as gates facilitating metastatic spread.
These data show that di-GA exhibits three distinct anticancer activities: induction of apoptosis, cell-cycle arrest and disruption of cancer cell-induced lymphendothelial disintegration.
Digalloyl-resveratrol (di-GA) is a synthetic ester of the phytoalexin resveratrol (3,4′,5-trihydroxystilbene; RV) and the polyhydroxy phenolic compound gallic acid (3,4,5-trihydroxybenzoic acid; GA) (Figure 1). Gallic acid can be found in various natural products, such as green tea, pineapples, bananas, apple peels, red and white wine (Sun et al, 2002; De Beer et al, 2003; Wolfe et al, 2003). Resveratrol is a constituent of red wine and grapes. Both compounds are proposed to contribute to the ‘French Paradox', a phenomenon of significantly lower (40%) heart infarction incidence in the French population, when compared with other European countries or the United States (Richard, 1987; Renaud and De Lorgeril, 1992; Constant, 1997). Gallic acid and RV were also described as excellent free radical scavengers (Inoue et al, 1994; Isuzugawa et al, 2001; Kawada et al, 2001; Salucci et al, 2002; Sohi et al, 2003; Horvath et al, 2005) and as inducers of differentiation and programmed cell death in a variety of tumour cell lines. Other beneficial properties of GA-containing fruit extracts include anti-diabetic and anti-angiogenic effects (Liu et al, 2005; Sridhar et al, 2005). Gallic acid is also present at high concentrations in gallnuts (name), which are proliferations of plant leaves that become elicited by gall wasp exudates to build up a hatchery for their larvae. Thus, the secretion of gall wasps stimulates plant cell growth and overrules homeostasis of the affected leaf area – this is similar to tumour outgrowth. In turn, the plant produces GA, which seems to combat the improper growth signals and re-establishes cell-cycle control. This could at least explain why gallnuts are rich in GA and that gallnuts do not grow beyond a certain size. This cytostatic property of GA – which is amplified in di-GA – seems to be one of the cancer-protective principles of a variety of fruits and this could also be developed for adjuvant therapy.
Gallnuts are not used in modern western medicine, but they were mentioned in the first book of ‘De Materia Medica' ascribed to Pedanios Dioscurides (the ‘Vienna Dioscurides', Austrian National Library, which was written in the sixth century in Konstantinopolis, East Roman Empire). Interestingly, this manuscript claims that gallnuts ‘stop the growth of proliferating tissue'. Other studies showed that RV and GA are effective inhibitors of the enzyme ribonucleotide reductase (RR; EC18.104.22.168) (Fontecave et al, 1998; Madlener et al, 2007). Ribonucleotide reductase is significantly upregulated in malignant cells compared to non-malignant cells. This enzyme catalyses the rate-limiting step of de novo DNA synthesis, which is the reduction of ribonucleotides into the corresponding deoxyribonucleoside triphosphates (dNTPs). This qualifies RR as an excellent target for cancer chemotherapy.
Apart from being a radical scavenger, the multifactorial effects of GA encompass also the inhibition of cyclooxygenases (COXs) and of lipoxygenases (LOXs). Tumours express high levels of COX-2 and 12-LOX (Nie et al, 2003; Pidgeon et al, 2003; Nassar et al, 2007), which metabolise arachidonic acid to prostanoids and to hydroxyeicosatetraenoic acids (12(S)-HETE), respectively (Marks et al, 2000). Certain HETEs function as inter- and intracellular messengers and cause the repulsion of endothelial cells thereby forming gaps in the endothelial cell layer (Ohigashi et al, 1989; Nakamori et al, 1997; Uchide et al, 2007). Further, these gaps may serve as entry ports for adjacent tumour cells into the lymphatic system. Thus, we hypothesised that GA (and di-GA) may inhibit lymphendothelial gap formation. Here we examine the effects of di-GA on apoptosis, cell-cycle progression and lymphendothelial gap formation.
Nordihydroguaiaretic acid (NDGA) was from Cayman Chemical (Ann Arbor, MI, USA); and aspirin, mannitol, probucol, GA and RV were from Sigma-Aldrich (Vienna, Austria). Catalase and carboxy-PTIO were from Calbiochem-Merck Biosciences (Nottingham, UK). Berberine chloride dihydrate (purity 98.92%) was from Phytolab (Vestenbergsgreuth, Germany). Experimental stock solutions (in DMSO) were prepared always fresh.
Mouse monoclonal anti-Cdc25A (F-6) Cat. No. 7389; anti-PARP-1 (F-2) Cat. No. sc-8007; anti-cyclin D1 (M-20) Cat. No. sc-718; anti-cyclin E (M20) Cat. No. sc-481 and anti-p21Cip/Waf (C-19) Cat. No. sc-397 antibodies were from Santa Cruz Biotechnology Inc. (Heidelberg, Germany). Polyclonal anti-phospho-Cdc25A (Ser17) Cat. No. ab18321 antibody was from Abcam (Cambridge, UK); and monoclonal anti-p34Cdc2 Cat. No. C3085 and anti-β-actin (AC15) Cat. No. A5441 antibodies were from Sigma-Aldrich. Rabbit monoclonal anti-cleaved caspase 3 (CPP32) clone C92-605 Cat. No. 58404 antibody was from Research Diagnostics Inc. (Flanders, NJ, USA). Polyclonal anti-MEK 1/2 Cat. No. 9122; anti-phospho-MEK 1/2 (Ser217/221) Cat. No. 9121 m; anti-phospho-Chk2 (Thr68) Cat. No. 2661; anti-Chk2 Cat. No. 2662 and rabbit monoclonal anti-p44/42 MAP Kinase (137F5) Cat. No. 4695; anti-phospho-Cdc2 (Tyr15) Cat. No. 4539 and mouse monoclonal anti-phospho-p44/42 MAPK (Thr202/Tyr204) (E10) Cat. No. 9106 antibodies were from Cell Signaling Technology Inc. (Danvers, MA, USA). Anti-mouse IgG was from Dako (Vienna, Austria). Anti-rabbit IgG and Amersham ECL – high-performance chemiluminescence film – were from GE Healthcare (Vienna, Austria).
HL-60 human promyelocytic cells were purchased from ATCC (Wesel, Germany). Cells were grown in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum, 1% L-glutamine and 1% penicillin/streptomycin. MCF-7 cells were grown in McCoy 5A medium containing 10% fetal calf serum and 1% penicillin/streptomycin. Human normal lung fibroblasts (HLF) were a generous gift of the Cancer Research Institute of the Medical University of Vienna and were grown in RPMI medium containing 10% fetal calf serum and 1% penicillin/streptomycin. All media, supplements and G418 were obtained from Life Technologies (Lofer, Austria).
Human dermal microvascular endothelial cells (C-12260) were purchased from PromoCell (Heidelberg, Germany). To obtain a population of highly enriched lymphendothelial cells (LECs) dermal microvascular endothelial cells were sorted with polyclonal rabbit anti-human podoplanin antibody and sheep anti-rabbit dynabeads (M-280; Dynal 11203; Invitrogen, Lofer, Austria). Subsequently, residual cells were sorted with anti-CD31 (Dynal 11128). Incubations were performed at 4°C for 30min. Such isolated LECs were stable transfected with telomerase cDNA and then maintained in EGM2 Mv medium (EBM2-based medium CC3156 and supplement CC4147; Lonza, Walkersville, MD, USA) and G-418 (Schoppmann et al, 2004). All cell types were kept in humidified atmosphere containing 5% CO2 at 37°C.
HL-60 cells were seeded in T-25 tissue culture flasks at a concentration of 1 × 105 per ml and incubated with increasing concentrations of di-GA (2.5, 5, 7.5, 10 and 40μM). Cell numbers and IpC50 values were determined after 24 and 48h using a CC-108 microcellcounter (Sysmex, Kobe, Japan).
The extraction of cellular dNTPs was performed according to a method described previously (Garrett and Santi, 1979). HL-60 cells (7 × 107) were incubated with 5, 10 and 40μM di-GA for 24h. Then, 1 × 108 were centrifuged at 1800r.p.m. and resuspended in 100μl phosphate-buffered saline (PBS) and extracted with 10μl trichloroacetic acid. The lysate was rested on ice and neutralised by adding 1.5 vol of freon containing 500μM tri-n-octylamin. Afterwards the lysate was centrifuged (15000r.p.m. for 4min) and the supernatant was used for periodation (100μl extract +30μl 4M methylamine (pH 7.5)+10μl periodat). Aliquots (120μl) of each sample were analysed using a Merck ‘La Chrom' HPLC-system equipped with D-7000 interface, L-7100 pump, L-7200 autosampler and L-7400 UV-detector. Detection time was set at 80min, the detector operated on 280nm for 40min and then switched to 260nm for another 40min. Samples were eluted with a 3.2M ammonium phosphate buffer, pH 3.6 (pH adjusted by addition of 3.2M H3PO4), containing 20moll−1 acetonitrile using a 4.6 × 250mm Partisil 10 SAX column (Whatman Ltd., Kent, UK). Separation was performed at constant ambient temperature and at a flow rate of 2mlmin−1. The concentrations of each dNTP of the experimental samples were then calculated as percent of total area under the control curves. Chemicals were from Sigma-Aldrich and of highest available quality.
The vitality staining was performed according to a protocol described before (Grusch et al, 2002). HL-60 cells (0.4 × 106 per ml) were seeded in T-25 tissue culture flasks and exposed to increasing concentrations of di-GA (2.5, 5, 7.5, 10 and 40μM) for 24h. Hoechst 33258 and propidium iodide were purchased from Sigma-Aldrich and added directly to the cells at final concentrations of 5 and 2μg/ml, respectively. After 60min of incubation at 37°C, we examined cells with a Zeiss Axiovert fluorescence microscope and a DAPI filter (Carl Zeiss, Jena, Germany). Cells were photographed and analysed by visual examination (not by FACS). This method allows to distinguish between early apoptosis, late apoptosis and necrosis. Cells were judged according to their nuclear morphology and the disintegration of their cell membranes, which is indicated by propidium iodide uptake.
HL-60 cells (0.4 × 106 per ml) were seeded in T-25 tissue culture flasks and incubated with 2.5, 5, 10 and 40μM di-GA. After 24h, cells were harvested, washed with 5ml cold PBS, centrifuged (600r.p.m. for 5min) and resuspended and fixed in 3ml ethanol (70%) at 4°C for 30min. After two further washing steps with cold PBS, RNAse A and propidium iodide were added to a final concentration of 50μgml−1 each and incubated at 4°C for 60min before analysis on a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). The cell-cycle distribution was calculated with ModFit LT software (Verity Software House, Topsham, ME, USA).
Exponentially growing HL-60 cells (5 × 105) were incubated with 1, 2.5 and 5μM di-GA for 24h at 37°C in a humidified atmosphere containing 5% CO2 to assess changes in RR in situ activity. Then, cells were pulsed with 14C-cytidine (Sigma-Aldrich; 3μl in a 5ml cell suspension) at 37°C for 30min, collected by centrifugation (1200r.p.m. for 5min), washed twice with PBS and processed to extract total genomic DNA. Thereafter, the radioactivity, which became incorporated into genomic DNA, was measured.
HL-60 cells (1.5 × 107 cells) were seeded into T-75 tissue culture flasks and incubated with 10μM di-GA for 0.5, 2, 4, 8 and 24h. Then, 1 × 106 cells were harvested (per experimental point), washed twice with cold PBS, centrifuged at 1000r.p.m. for 5min and lysed in a buffer containing 150mM NaCl, 50mM Tris (pH 8.0), 1% Triton X-100, 1mM phenylmethylsulfonyl fluoride and protease inhibitor cocktail (from a × 100 stock; Sigma-Aldrich). The lysates were centrifuged at 4°C for 20min (12000r.p.m.) and supernatants stored at −20°C until further analysis. Equal amounts of protein samples were separated by polyacrylamide gel electrophoresis and electroblotted onto PVDF membranes (Hybond, GE Healthcare) at 4°C overnight. Equal sample loading was controlled by staining membranes with Poinceau S (Sigma-Aldrich). After washing with PBS/0.5% Tween 20 (PBS/T) (pH 7.2) or TBS/0.1% Tween 20 (TBS/T) (pH 7.6), membranes were blocked for 1h in blocking solution (5% non-fat dry milk in PBS/T or in TBS/T). The membranes were incubated with the first antibody (in blocking solution, dilution 1:500–1:1000) by gently rocking at 4°C overnight. Thereafter, the membranes were washed with PBS or TBS and further incubated with the second antibody (peroxidase-conjugated goat anti-rabbit IgG or anti-mouse IgG, dilution 1:2000–1:5000 in PBS/T or TBS/T) for 12h. Chemoluminescence was developed by the ECL detection kit and the exposure of membranes to Amersham Hyperfilms (GE Healthcare).
1.2g of autoclaved methyl cellulose (M-0512; Sigma-Aldrich) was resuspended in 100ml prewarmed McCoy 5A medium (Life Technologies; 1.2% stock concentration), stirred until the solution turned clear and centrifuged at 4000r.p.m. (swing out rotor) for 2h to pellet undesired debris. Then, 1 × 105 MCF-7 cells were transferred to 15ml McCoy 5A medium containing 0.24% methyl cellulose (final concentration). 150μl (containing ~1 × 103 cells) was transferred to each well of a round bottom microtitre plate (96-well) to allow spheroid formation. Cells were allowed to aggregate and grow for 2 days, and then spheroids were sufficiently dense for further manipulations. MCF-7 spheroids had an average diameter of ~300μm.
LECs were seeded in EGM2 MV medium on 24-well plates and allowed to grow for 2–3 days until confluence. Then, LECs were stained with cytotracker green (concentration 2μgml−1 final concentration, Molecular Probes-C2925, Invitrogen) at 37°C for 90min and subsequently rinsed thoroughly. Thereafter, MCF-7 spheroids were washed in EGM2 MV medium to rid off methyl cellulose, and 12 spheroids were carefully transferred using wide bore yellow tips to each well containing LECs.
For those experiments in which inhibitors were used, the indicated inhibitor concentrations (final concentrations) were applied to the spheroids 30min prior addition of the spheroids to the LEC layers.
LEC areas with spheroids on top were photographed using an FITC filter, which was used to visualise cytotracker (green)-stained LECs underneath the spheroids. Axiovert software (Carl Zeiss) facilitated to measure the gap areas within the LEC layers.
Dose–response curves were calculated using the Prism 4.03 software package (GraphPad, San Diego, CA, USA) and statistical significance was determined by two-tailed paired t-test (significance P<0.05).
Quite a few studies on GA and its derivatives, RV and RV analogues were performed in human leukaemia cells (Saiko et al, 2008), because these cells are very sensitive to drugs and therefore advantageous to test the efficacy of novel anticancer compounds. HL-60 cells are particularly useful to discriminate the nuclear morphology of necrotic and apoptotic cells (Grusch et al, 2002) and hence, we used HL-60 cells to study di-GA facilitating the comparability of our results with published data of other GA and RV analogues.
The pro-apoptotic potential of naturally occurring GA was compared to that of synthetic di-GA by incubating HL-60 promyelocytic leukaemia cells to both agents (Figure 2A and B). Increasing concentrations of GA (10, 20, 40 and 80μM) elicited 4, 10, 34 and 60% apoptosis, respectively. Because the di-GA molecule contains two galloyl residues (as compared to just one gallic acid molecule of GA) we expected that half of the di-GA concentrations would induce similar apoptosis rates as the tested GA concentrations. However, 5, 10 and 40μM di-GA (to compare it to 10, 20 and 80μM GA, see above) triggered 12, 39 and 84% apoptosis, respectively. In an earlier study, we showed that 25 and 50μM RV induced ~18 and 45% apoptosis in HL-60 cells, respectively (Horvath et al, 2006). Therefore, the apoptotic efficiency of di-GA is the sum of the apoptotic properties of 2 × GA plus RV. Apoptosis correlated with the activation of caspase 3 and with the signature type cleavage of PARP into an 85kDa fragment (Figure 2C). Digalloyl-resveratrol did not induce significant numbers of necrotic cells even at high concentrations (data not shown). The data suggest that di-GA is a potent inducer of apoptosis and significantly more effective than GA alone.
HL-60 cells were exposed to increasing concentrations of GA and di-GA and the cell numbers were measured after 24 and 48h. The percentages of proliferation inhibition were calculated at both time points. Those concentrations that inhibited 50% proliferation (IpC50) are shown in Table 1. Digalloyl-resveratrol inhibited proliferation 7–10 times more efficiently than GA during the tested time period. Inhibition of cell proliferation was due to a dose-dependent cell-cycle block in G1 (Figure 3A).
We next examined the levels of the cell-cycle inhibitor p21Cip/Waf, which is known to inhibit Cdk2 by blocking its interaction with cyclin E (Jeon et al, 2007). p21Cip/Waf was induced within 4h (Figure 3B), which was independent of p53, because HL-60 cells are p53 negative (Biroccio et al, 1999). Phosphorylation of Erk1 and MEK, which is indicative for their activation, preceded the increase in p21Cip/Waf levels. This is consistent with previous reports that MEK-Erk signalling upregulates p21Cip/Waf (Facchinetti et al, 2004; Park et al, 2004; Perez-Pinera et al, 2006). Phosphorylation of Erk2 (the lower band occurring after 4 and 8h) was simultaneous to p21Cip/Waf upregulation. Next, we investigated whether the expression of the G1-specific cell-cycle regulators Cdc25A, cyclin D1 and cyclin E was altered by di-GA treatment (10μM). Western blot analyses showed that cyclin D1 expression decreased after 2h and remained suppressed, whereas cyclin E expression persisted (Figure 3C). Cyclin D1 is required for the activation of Cdk4 and Cdk6 (Lingfei et al, 1998; Alao, 2007), which altogether is controlled by Cdc25A (Iavarone and Massague, 1997). Digalloyl-resveratrol strongly induced serine 17 (Ser17) phosphorylation of Cdc25A after 4h. Phosphorylation of Ser17-Cdc25A was shown to stabilise this phosphatase at a high activity status specifically in the M phase (Mailand et al, 2002), thereby de-phosphorylating and activating its target Cdk1 (Cdc2). This is mandatory for the transit through the G2-M phase (Karlsson-Rosenthal and Millar, 2006). Hence, Cdc25A controls not only the G1-S, but also the G2-M phase. Indeed, di-GA caused the de-phosphorylation of Tyr15-Cdc2 indicating that cells entered the mitotic phase. FACS analysis confirmed that 40μM di-GA allowed ~90% of the cells to pass through S and M phase (likely due to Cdc25A activity) but accumulated in the subsequent G1 phase because cyclin D1 was repressed. Finally, Cdc25A protein level decreased after 24h. This was paralleled by Chk2 activation (indicated by its phosphorylation at Thr68), presumably due to replicatory stress. Chk2 targets Cdc25A for proteolytic degradation (Karlsson-Rosenthal and Millar, 2006). In summary, the data suggest that di-GA inhibits cell proliferation by disturbing orchestrated mitogenic signalling.
Gallic acid is a radical scavenger (Whang et al, 2005) and inhibits RR through chelating the tyrosyl radical required for RR activity (Madlener et al, 2007). Ribonucleotide reductase is the rate-limiting enzyme for nucleotide metabolism necessary for DNA synthesis during cell division.
Hence, RR activity was investigated by an assay that measures the incorporation of 14C-cytidin into genomic DNA. Figure 4A shows that 14C-cytidin incorporation into genomic DNA decreased with increasing di-GA concentration. Further, RR activity was fully blocked on treatment with 5μM di-GA. At this concentration the dCTP level (but not dTTP and dATP) dropped significantly (Figure 4B). In HT29 colon carcinoma cells, a similar effect of di-GA on RR activity, dCTP, dTTP and dATP levels was observed (Bernhaus et al, 2009).
Leukocytes trespass basal membranes and trans-migrate tissues and endothelia as part of their normal physiological function and are therefore, a priori ‘invasive'. Hence, HL-60 leukaemia cells are inappropriate to study the pathological invasiveness of cancer cells and the anti-invasive/anti-metastatic potential of di-GA. In contrast, solid tumours acquire an invasive potential in course of cancer progression and this particular cancer cell property has to be studied and combated. We developed a novel bulk invasion assay to establish an in vitro model resembling the pathologic situation of ductal breast cancer cells invading the lymphatic vasculature and to recapitulate the mechanism of metastasis (Ohigashi et al, 1989; Nakamori et al, 1997; Uchide et al, 2007). For this, telomerase immortalised human LECs were grown to confluent monolayers and MCF-7 tumour spheroids (average diameter ~300μm, containing ~4000 cells) were placed on top to mimic tumour intrusion into lymphatics. Lymphendothelial cells were pre-labelled with cyto-tracker (green) immediately before co-cultivation, to monitor presence or absence of LECs underneath tumour spheroids (Figure 5A). Normal HLF spheroids served as negative controls, because these primary cells with limited lifespan (Hayflick limit) are non-malignant and do not invade blood or lymphatic vasculature. After 4h of co-cultivation, gaps formed underneath >99% of the MCF-7 tumour spheroids (gap area was on average ~1.15 × 105μm2) whereas no or only small gaps were formed underneath normal lung fibroblasts. The gap size area was measured underneath at least 12 spheroids and in triplicate experiments. These gaps resemble entry ports for cancer cell bulks invading the lymphatic system, which is now widely accepted to be a route for the spreading of certain cancers (Alitalo et al, 2005; Oliver and Alitalo, 2005; Sipos et al, 2005).
Di-GA inhibited gap formation dose-dependently and maximally by >60% (Figure 5B). We have evidence (time-laps movies; data not shown) that gap formation is caused by LEC migration. Berberine was reported to inhibit cell migration and invasion of SCC-4 tongue squamous cancer cells (Ho et al, 2009) and HONE1 nasopharyngeal cancer cells (Tsang et al, 2009). The chemical structure of berberine is reminiscent to parts of di-GA and for control reasons we tested whether berberine had an effect on MCF-7-induced LEC behaviour. Berberine dose-dependently inhibited gap formation and this confirmed that the assay was functional and responded according to prediction.
Primary cancers and also MCF-7 breast cancer cells express elevated levels of LOXs, which metabolise arachidonic acid to HETEs (Marks et al, 2000; Nie et al, 2003; Kudryavtsev et al, 2005). The migration of endothelial cells was shown to be mediated by LOXs generating 12(S)-HETE (Ohigashi et al, 1989; Nakamori et al, 1997; Uchide et al, 2007). 12(S)-HETE functions as inter- and intracellular messenger and causes the retraction of endothelial cells, thereby forming gaps into the confluent cell layer. The 12/15-LOX inhibitors baicalein (100μM) and NDGA (50μM) reduced the area of MCF-7 spheroid-induced gaps in the LEC monolayers by ~50 and 60%, respectively. Derivatives of GA are also known to inhibit HETE generating LOXs, and prostanoids generating COXs (Christow et al, 1991; Ha et al, 2004; Kim et al, 2006). However, because aspirin had no effect on gap formation (Figure 5B) the contribution of COXs can be excluded. We also took into account that NDGA, baicalein, GA and di-GA are powerful radical scavengers and antioxidants (Sohi et al, 2003; Floriano-Sanchez et al, 2006). In case LEC gaps were induced by radicals, gap formation should be inhibited by radical scavengers. To test this possibility, we analysed the efficacy of four bona fide ROS scavengers. In particular, we used mannitol, which scavenges the OH• radical; probucol, which is an effective inhibitor of lipid peroxidation; catalase, which is an H2O2 catabolising enzyme; and carboxy-PTIO, which scavenges the NO• radical. These scavengers did not prevent LEC gap formation. Therefore, MCF-7-induced gap formation was independent of a potential radical involvement.
Finally, we tested whether isolated GA and RV inhibited LEC gap formation. Whereas 50μM RV inhibited gap size by ~25%, 80μM GA was ineffective. Therefore, GA did not affect cell migration, which was in contrast to a galloyl glucose derivate that inhibited tube formation of human microvessel endothelial cells (Lee et al, 2004). Methyl gallate influences 5-LOX (Kim et al, 2006) and GA may also inhibit this enzyme. However, 5-LOX did not contribute to LEC gap formation, because 100μM caffeic acid did not reduce gap size (data not shown). This indicated that RV, but not GA, was the inhibitory principle being improved by the higher complex structure of di-GA.
In summary, di-GA dose-dependently inhibited LEC gap formation with an efficiency similar to that of NDGA. The strong anti-invasive property of di-GA is apparently due to the novel chemical structure of the compound, but not due to the GA residues, and only in part due to RV.
Gallic acid is a polyhydroxylated phenol previously known to scavenge radicals, inhibit RR, COXs, LOXs, arrest cell cycle and induce apoptosis (Ha et al, 2004; Faried et al, 2007; Hsu et al, 2007; Madlener et al, 2007).
Here we tested a novel synthetic GA derivate, di-GA, assuming that this compound may exhibit superior activity than GA itself. In fact, the pro-apoptotic property of 10μM di-GA exceeded that of 20μM GA by four-fold. Thus, an additional pro-apoptotic mechanism, apart from two galloyl residues, contributed to cell death especially at low concentrations. This is of particular interest because such concentrations can be achieved in humans. The RV backbone, to which the galloyl residues are connected, may be responsible for the additive effect, because RV was previously reported to induce apoptosis in HL-60 cells (Horvath et al, 2006). The apoptotic activity of di-GA was much higher than the reported RV activity (50μM RV induced 50% apoptosis in HL-60), but the apoptotic activity of the RV derivative, 3,3′,4,4′,5,5′-hexahydroxystilbene (M8) was even higher than that of di-GA (Horvath et al, 2006). In contrast, another RV derivative with anti-neoplastic properties, N-hydroxy-N′-(3,4,5-trimethoxyphenyl)-3,4,5-trimethoxy-benzamidine (KITC), induced HL-60 apoptosis less efficiently (Saiko et al, 2007). Digalloyl-resveratrol triggered apoptosis through the caspase 3 pathway yet independent of p53, because HL-60 cells are p53 deficient (Biroccio et al, 1999). Because more than 50% of all cancer types harbour a defective p53 pathway, which is detrimental to successful therapeutic treatment, compounds that exert anticancer activity independent of p53 are of particular interest for clinical applications.
Another prominent anticancer property of therapeutic drugs is to arrest the cell cycle. This can be achieved by blocking distinct mechanisms such as cell-cycle regulators or enzymes involved in DNA-replicative processes etc. Here we show that di-GA inhibited cell proliferation 10-fold more efficiently than GA (Madlener et al, 2007). This again suggests that the RV backbone synergised with the two galloyl residues. Similar to GA, di-GA also inhibited HL-60 cell cycle in G1 (Madlener et al, 2007). Resveratrol and its analogue M8 were shown to inhibit the cell cycle in S phase (Ragione et al, 1998; Horvath et al, 2006) and, therefore, the G1-inhibitory effect of the GA moieties was dominant over that of the RV backbone in the di-GA molecule. Interestingly, also KITC inhibited the HL-60 cell cycle in G1 phase (Saiko et al, 2007). Digalloyl-resveratrol caused cell-cycle arrest by four independent mechanisms:
It has been shown that MCF-7 cells induce gap formation into arterial endothelial cell layers by virtue of 12(S)-HETE secretion, which is generated by LOXs metabolising arachidonic acid (Kudryavtsev et al, 2005; Uchide et al, 2007). Gap formation was due to LEC migration (retraction) but not due to apoptosis of LECs, which was evidenced by microscopic time-laps movies (not shown) and by berberine-mediated inhibition of migration (Ho et al, 2009; Tsang et al, 2009). We extended this cell system using a three-dimensional co-culture model consisting of MCF-7 spheroids and telomerase-immortalised primary human LECs (Schoppmann et al, 2004), because this closely resembles ductal breast cancer bulks intruding the lymphatic vasculature. We showed that MCF-7-triggered lymphendothelial gap formation could be reduced to 40% by NDGA, which is a potent inhibitor of 12/15-LOXs but also a radical scavenger. Several gallate derivates are known to inhibit LOXs (Christow et al, 1991; Ha et al, 2004; Kim et al, 2006), to scavenge radicals (Whang et al, 2005) and to inhibit COX (Madlener et al, 2007; Kim et al, 2006). However, neither radicals nor COXs contributed to gap formation. Hence, baicalein- and NDGA-mediated inhibition supports the notion that at least 50–60% of gap formation was due to 12(S)-HETE generating LOX activity. The property of di-GA that reduced LEC migration was similar to that of NDGA. Also the tube formation of human microvessel endothelial cells, which was inhibited by a galloyl glucose derivate, was most likely due to the inhibition of cell migration (Lee et al, 2004). Because 12/15-LOX contributes to angiogenesis (Nie et al, 2000, 2006; Rose and Connolly, 2000) and tumour metastasis (Liu et al, 1996; Jankun et al, 2006), di-GA may prevent neo-vascularisation of tumours as well as infiltration of cancer cells into the lymphatic vasculature. Another derivate, galloyl glucose, blocked HT-1080 tumour invasion through gelatin by inhibiting matrix metalloprotease-2 (MMP-2) and MMP-9 (Ata et al, 1996). In our system, specific inhibition of MMP-2 and MMP-9 with cell permeable small molecules exhibited only a weak effect on MCF-7-mediated gap formation into LEC layers (data not shown). Interestingly, 80μM GA did not decrease lymphendothelial gap formation whereas 50μM RV inhibited gap formation by 25% evidencing that the principal inhibitory activity was contributed by RV and that the superior activity of di-GA was not the sum of RV plus GA, but a new property of its own.
This is analogous to the observation that the RV derivate M8 exhibits not only improved but even new anti-neoplastic properties. In particular, M8 inhibits ROCK1 expression in contrast to RV, which even induces ROCK1 protein levels (Paulitschke et al, 2009). ROCK1 supports migration, invasivity and lymph node metastasis of melanoma cells. M8 inhibits melanoma lymph node metastasis in an scid mouse model by ~50% at a concentration that is comparable to 50μM used in vitro (Paulitschke et al, 2009). Interestingly, LEC gaps induced by melanoma spheroids could not be inhibited by NDGA or baicalein suggesting that different cancer types invade the lymphatic vasculature by a mechanism different of LOX. In addition to the effects described above, RV and M8 are shown to inhibit NF-κB (Holmes-McNary and Baldwin, 2000; Horvath et al, 2006). In preliminary investigations we found that specific inhibition of NF-κB by small molecules significantly attenuated LEC gap formation (data not shown). Whether di-GA affects ROCK1 expression and/or NF-κB translocation remains to be established. DMU-212 (3,4,5,4′-tetramethoxystilbene) is another RV derivate that exerts strong anti-neoplastic effects in breast carcinoma cells by tubulin polymerisation, which is a mechanism not induced by RV (Ma et al, 2008). Other approaches focus on RV analogues with improved cellular uptake properties such as a triacetate form of RV or vineatrol that both retain the anti-neoplastic properties of RV (Colin et al, 2009).
In conclusion, we describe three distinct anticancer effects of di-GA: the induction of apoptosis, the inhibition of cell division and the inhibition of gap formation into lymphendothelial layers. Further, we provide mechanistic explanations for the effect of di-GA on apoptosis and cell cycle. For gap formation, we show the affection of cell motility; however, an exact mechanism awaits elucidation.
We thank Toni Jäger for preparing the figures, and Professor Max J Scott, Massey University, Palmerston North, NZ, for carefully reading and styling the article. The work was supported by the Unruhe Privatstiftung, the Funds for Innovative and Interdisciplinary Cancer Research, and the Hochschuljubiläumsstiftung der Stadt Wien to GK; the Funds for Innovative and Interdisciplinary Cancer Research, and the Fonds zur Förderung der Wissenschaftlichen Forschung des Bürgermeisters der Bundeshauptstadt Wien, grant number 09059 to MF-S; the Hochschuljubiläumsstiftung der Stadt Wien to TS, and the Austrian Science Fund, FWF, Grant Numbers P19598-B13 and SFB F28, and the Herzfelder Family Foundation (to WM).